89 completed, 23 recruiting, 19 active not recruiting, 14 terminated. 109 Phase 2, 55 Phase 1, 27 Phase 3, 1 Not applicable, 1 Phase 4.
Follow Ramucirumab: new trials by email Literature Review of Ramucirumab trials Research Report on Ramucirumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Biospecimen Collection, Computed Tomography, Futibatinib - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Phase 1 | Not yet recruiting | Northwestern University | 18 | 2027-09-09 | 2026-10-20 |
| A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Telisotuzumab Adizutecan, Docetaxel, Ramucirumab - Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | AbbVie | 660 | 2027-01-06 | 2026-10-05 |
| A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | University of Chicago | 39 | 2026-12-12 | 2026-06-16 |
| Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), CAPOX (oxaliplatin/capecitabine), CDDP, 5 Fu - Gastroesophageal Adenocarcinoma | Phase 3 | Not yet recruiting | Gruppo Oncologico del Nord-Ovest | 244 | 2026-09-01 | 2026-08-18 |
| Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy AMT-116, Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Multitude Therapeutics Inc. | 512 | 2026-08-28 | 2026-08-10 |
| Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas Denikitug, Nivolumab, Ramucirumab - HER2-negative, Gastroesophageal Junction | Phase 2 | Recruiting | Gilead Sciences | 120 | 2026-08-07 | 2026-09-21 |
| A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy Sintilimab Combined with Ramucirumab and Paclitaxel - Gastric Cancer (Diagnosis) | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 30 | 2026-07-01 | 2026-06-25 |
| A Platform Study in Non-Small Cell Lung Cancer (NSCLC) Rilvegostomig, Cisplatin, Carboplatin - Advanced or Metastatic Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 152 | 2025-11-24 | 2026-10-01 |
| Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases Biopsy, Biospecimen Collection, Computed Tomography - Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 30 | 2025-10-29 | 2025-11-10 |
| A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) Rilvegostomig, Ramucirumab, Dato-DXd - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | AstraZeneca | 278 | 2025-08-07 | 2026-10-15 |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) Biospecimen Collection, Cemiplimab, Computed Tomography - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 / Phase 3 | Recruiting | SWOG Cancer Research Network | 378 | 2025-05-22 | 2026-10-09 |
| Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors HCB101, Trastuzumab, Pertuzumab - Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | FBD Biologics Limited | 500 | 2025-03-13 | 2026-02-04 |
| Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil - Metastatic Gastro-esophageal Adenocarcinoma | Phase 2 | Active not recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 126 | 2025-03-03 | 2026-01-07 |
| Volrustomig Priming Regimens Exploratory Phase II Platform Study Volrustomig, Carboplatin, Pemetrexed - Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 194 | 2024-08-27 | 2026-09-29 |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) Biospecimen Collection, Computed Tomography, Lymphoscintigraphy - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 56 | 2024-08-08 | 2026-10-09 |
| Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan - Gastroesophageal Junction, Gastroesophageal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 210 | 2024-08-07 | 2026-09-03 |
| A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis Sintilimab, Ramucirumab, SOX/XELOX - Stomach Neoplasms | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 39 | 2024-08-01 | 2024-08-28 |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 224 | 2024-06-24 | 2026-10-21 |
| Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy Cadonilimab Injection, Ramucirumab Injection - Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy | Phase 1 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2024-06-01 | 2024-04-15 |
| Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma Paclitaxel, Ramucirumab, Zanidatamab - Gastroesophageal Adenocarcinoma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 168 | 2024-04-16 | 2026-08-11 |
Showing 20 of 172. Sign in to see all of them.
Stomach Neoplasms (41) · Carcinoma, Non-Small-Cell Lung (37) · Neoplasms (14) · Lung Neoplasms (13) · Adenocarcinoma (11) · Neoplasm Metastasis (11) · Colorectal Neoplasms (9) · Adenocarcinoma Of Esophagus (7) · Carcinoma, Hepatocellular (7) · Esophageal Neoplasms (7) · Breast Neoplasms (5) · Carcinoma, Renal Cell (5) · Colonic Neoplasms (5) · Biliary Tract Neoplasms (3) · Carcinoma, Transitional Cell (3)
Eli Lilly and Company (62) · SWOG Cancer Research Network (9) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (6) · Washington University School of Medicine (5) · AstraZeneca (3) · City of Hope Medical Center (3) · Memorial Sloan Kettering Cancer Center (3) · National Cancer Institute (NCI) (3) · ALX Oncology Inc. (2) · Astellas Pharma Global Development, Inc. (2) · Bristol-Myers Squibb (2) · Hellenic Cooperative Oncology Group (2) · Samsung Medical Center (2) · Sanofi (2) · The First Affiliated Hospital with Nanjing Medical University (2)
United States (114) · South Korea (38) · Spain (36) · Japan (35) · Germany (32) · Italy (30) · France (29) · Taiwan (27) · United Kingdom (24) · Australia (22) · Belgium (20) · Canada (20) · China (17) · Israel (12) · Poland (12)
Salah-Eddin Al-Batran, Prof. Dr. (3) · Daniel Morgensztern, M.D. (2) · Douglas R Adkins, M.D. (2) · Karen L Reckamp (2) · Koichi Takiguchi, PhD (2) · Paul K Paik (2) · Yelena Janjigian, MD (2) · Afsaneh Barzi, MD (1) · Anne S Tsao (1) · Anwaar Saeed (1)
PMID 34795131, PMID 28716815, PMID 28950290, PMID 30557792, PMID 32107609, PMID 32817068, PMID 33188713, PMID 33531690, PMID 35247922, PMID 10555755, PMID 11123390, PMID 11230497, PMID 11489791, PMID 11895891, PMID 14963856, PMID 16271446, PMID 1651156, PMID 17468871, PMID 18268188, PMID 19220526, PMID 19349540, PMID 21502559, PMID 22811849, PMID 22853980, PMID 23275061, PMID 23406728, PMID 23880820, PMID 24094768, PMID 24919854, PMID 24930625, PMID 24933332, PMID 25016924, PMID 25146529, PMID 25185099, PMID 25202099, PMID 25240821, PMID 25377507, PMID 25396308, PMID 25403584, PMID 25577133, PMID 25787923, PMID 25877855, PMID 25888272, PMID 26082390, PMID 26095784, PMID 26510663, PMID 26615328, PMID 26632545, PMID 26747859, PMID 26926681
U10CA180888 (10), 2014 (6), 2015 (6), 2018 (5), 2016 (4), 2008 (3), 2017 (3), 2023 (3), 2025 (3), 2009 (1), 2019 (1), P30CA014089 (1), P30CA015083 (1), P30CA033572 (1), P30CA060553 (1)